VIP · Research brief

VIP Neuroinflammation — Peptide Mechanisms | Real Peptides

Real Peptides Research TeamEditorial

Updated April 3, 202612 min read

60 WORDS

Short answer

Without VIP (vasoactive intestinal peptide) modulation, microglial cells in the central nervous system default to pro-inflammatory M1 activation during injury or disease. Releasing cytokines that amplify neuronal damage rather than resolve it. Research published in the Journal of Neuroinflammation demonstrates that VIP binding to VPAC receptors shifts this microglial phenotype toward M2 anti-inflammatory states, reducing TNF-α and IL-6 while upregulating…

Key takeaways

VIP reduces neuroinflammation by binding VPAC1 and VPAC2 receptors, triggering cAMP-dependent inhibition of NF-κB. The transcription factor driving pro-inflammatory cytokine expression in microglia and astrocytes.
Microglial phenotype shifts from M1 (pro-inflammatory) to M2 (anti-inflammatory) under VIP treatment, with arginase-1 expression increasing 4–5-fold and iNOS dropping by 50–70% within 12–24 hours in culture models.
Native VIP has a plasma half-life of 1–2 minutes due to DPP-IV degradation, requiring modified analogs (acetylated, stearylated, PEGylated) or intranasal/ICV delivery to achieve sustained receptor engagement.
Experimental autoimmune encephalomyelitis (EAE) studies show VIP reduces peak disease severity by 45–62% and CNS demyelination by approximately 38% compared to vehicle controls.
Stroke models using middle cerebral artery occlusion demonstrate 32–41% infarct volume reduction when VIP is administered within three hours of reperfusion, with efficacy correlating to M2 microglial density in the penumbra.
Blood-brain barrier integrity improves under VIP treatment through reduced MMP activity and preserved tight junction protein expression, decreasing Evans blue extravasation by up to 58% in neuroinflammatory models.

We've worked with research institutions investigating VIP neuroinflammation pathways across neurodegenerative disease models, traumatic brain injury protocols, and autoimmune encephalitis studies. The gap between standard anti-inflammatory approaches and VIP-mediated resolution comes down to mechanism. One blocks signals, the other rewrites the cellular response program.

What is VIP neuroinflammation and how does the peptide modulate CNS inflammatory responses?

VIP neuroinflammation refers to the regulatory role vasoactive intestinal peptide plays in central nervous system inflammation through VPAC1 and VPAC2 receptor activation. VIP binding triggers cAMP-dependent signaling cascades that suppress NF-κB activation in microglia and astrocytes, reducing pro-inflammatory cytokine production by 40–70% in experimental models while simultaneously increasing anti-inflammatory mediators. This dual action makes VIP a research target for conditions where neuroinflammation drives pathology. Multiple sclerosis, Alzheimer's disease, Parkinson's disease, and stroke recovery.

Yes, VIP demonstrably reduces neuroinflammation in preclinical models. But the mechanism matters more than the outcome. Standard anti-inflammatory compounds work through COX inhibition, corticosteroid receptor activation, or cytokine neutralization. VIP operates upstream: it prevents microglial M1 polarization before pro-inflammatory cascades initiate. A 2019 study in Glia showed VIP pre-treatment reduced LPS-induced microglial TNF-α secretion by 68% and IL-1β by 54%, while simultaneously increasing IL-10 by 3.2-fold. This article covers VIP's VPAC receptor mechanisms, microglial phenotype switching data, blood-brain barrier permeability challenges, and peptide stability considerations that determine experimental outcomes.

VIP Receptor Distribution and Neuroinflammatory Signaling Pathways

VIP exerts its anti-neuroinflammatory effects through two G-protein-coupled receptors: VPAC1 (expressed broadly across CNS cell types including neurons, astrocytes, and microglia) and VPAC2 (concentrated in suprachiasmatic nucleus, hippocampus, and cortical regions). Both receptors couple to Gs proteins, triggering adenylyl cyclase activation and cAMP elevation. The secondary messenger that phosphorylates cAMP response element-binding protein (CREB) and inhibits NF-κB nuclear translocation. NF-κB is the master transcription factor driving pro-inflammatory gene expression; blocking its activation prevents transcription of TNF-α, IL-1β, IL-6, and inducible nitric oxide synthase (iNOS).

The VPAC1 receptor shows higher affinity for VIP in microglial cultures, with binding constants in the nanomolar range (Kd ≈ 1–3 nM). When lipopolysaccharide (LPS) activates microglia toward the M1 phenotype, VPAC1 stimulation via VIP administration blocks the phosphorylation of IκB-α. The inhibitor protein that normally sequesters NF-κB in the cytoplasm. Without IκB-α degradation, NF-κB cannot translocate to the nucleus, and pro-inflammatory cytokine transcription drops by 50–75% depending on VIP concentration and exposure duration. This mechanism has been replicated across rodent models of experimental autoimmune encephalomyelitis (EAE), the standard animal model for multiple sclerosis.

VPAC2 receptors contribute additional neuroprotective signaling through ERK1/2 and PI3K/Akt pathway activation. These kinase cascades promote neuronal survival during inflammatory stress and enhance synaptic plasticity markers including brain-derived neurotrophic factor (BDNF). In hippocampal slice cultures exposed to inflammatory cytokines, VIP treatment (100 nM) preserved dendritic spine density and maintained long-term potentiation (LTP). Both of which degrade rapidly under neuroinflammatory conditions without peptide intervention.

Researchers working with VIP for neuroinflammation studies require precise receptor pharmacology data. Our team synthesizes VIP with exact amino-acid sequencing and purity verification via HPLC. Guaranteeing consistent VPAC receptor binding across experimental replicates. The difference between published-quality data and inconclusive results often comes down to peptide purity and reconstitution protocol adherence. We've seen institutions repeat entire study arms after discovering degraded peptide stocks compromised receptor affinity.

Microglial Phenotype Switching: M1 to M2 Transition Mechanisms

Microglia exist on a spectrum between M1 (classically activated, pro-inflammatory) and M2 (alternatively activated, anti-inflammatory/reparative) phenotypes. M1 microglia release reactive oxygen species (ROS), nitric oxide (NO), and pro-inflammatory cytokines that amplify neuronal injury. M2 microglia secrete IL-10, TGF-β, and growth factors that promote tissue repair and debris clearance. VIP neuroinflammation research demonstrates that this peptide doesn't simply suppress M1 activation. It actively drives phenotype conversion toward M2.

The molecular switch occurs through VIP-induced upregulation of arginase-1 (Arg1) and CD206, both canonical M2 markers. Arginase-1 competes with iNOS for L-arginine substrate; when Arg1 expression increases, iNOS-dependent NO production decreases proportionally. A 2021 study in Brain, Behavior, and Immunity quantified this shift: VIP treatment (10⁻⁸ M) increased microglial Arg1 mRNA expression by 4.7-fold within 12 hours, while simultaneously reducing iNOS mRNA by 63%. CD206 (mannose receptor) expression doubled under the same conditions, indicating functional M2 polarization rather than mere cytokine suppression.

This phenotype conversion translates to measurable neuroprotection. In rodent stroke models using middle cerebral artery occlusion (MCAO), VIP administration within three hours of reperfusion reduced infarct volume by 32–41% compared to vehicle controls. Immunohistochemistry revealed dense CD206+ microglial populations surrounding the penumbra (the salvageable tissue zone adjacent to dead tissue), whereas vehicle-treated animals showed predominantly CD16/32+ M1 microglia in the same regions. The M2-dominant environment correlated with preserved neuronal counts and reduced glial scar formation at 14-day endpoints.

Blood-brain barrier (BBB) integrity also improves under VIP-mediated M2 polarization. M1 microglia secrete matrix metalloproteinases (MMPs) that degrade tight junction proteins (claudin-5, occludin, ZO-1), increasing BBB permeability and allowing peripheral immune cell infiltration. M2 microglia produce tissue inhibitors of metalloproteinases (TIMPs) that block MMP activity. VIP treatment in EAE models reduced Evans blue dye extravasation. A BBB permeability marker. By 58% at peak disease, with corresponding increases in claudin-5 immunoreactivity at endothelial junctions.

VIP Stability, Delivery Challenges, and Peptide Modifications for Neuroinflammation Studies

Native VIP has a plasma half-life of approximately 1–2 minutes due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidase (NEP). This extreme instability creates experimental challenges: systemic administration requires continuous infusion or multiple daily injections to maintain therapeutic concentrations. Intranasal delivery bypasses first-pass metabolism and exploits olfactory/trigeminal nerve pathways for direct CNS access, extending effective half-life to 15–30 minutes. Still insufficient for chronic neuroinflammation models requiring sustained receptor engagement.

Researchers address this through peptide modifications or encapsulation strategies. Acetylation of the N-terminus or C-terminal amidation increases resistance to enzymatic cleavage, extending half-life to 20–45 minutes without sacrificing VPAC receptor affinity. Stearyl-VIP, a lipidated analog, shows even greater stability (half-life ~90 minutes) and enhanced BBB penetration due to increased lipophilicity. A 2020 study in Molecular Pharmaceutics demonstrated that stearyl-VIP delivered intranasally reduced hippocampal IL-1β levels by 71% in LPS-challenged mice, compared to 42% reduction with native VIP at equivalent molar doses.

PEGylation. Covalent attachment of polyethylene glycol chains. Represents another stability strategy. PEGylated VIP analogs resist DPP-IV cleavage and exhibit half-lives exceeding four hours, enabling once-daily dosing in rodent models. However, PEGylation reduces VPAC receptor binding affinity by 30–50% depending on PEG size and attachment site, requiring dose escalation to achieve equivalent receptor occupancy. Researchers must balance stability gains against potency losses when selecting modified peptides.

Intracerebral or intracerebroventricular (ICV) administration eliminates BBB permeability concerns but introduces surgical invasiveness unsuitable for repeated dosing. Convection-enhanced delivery (CED). Continuous infusion via implanted cannula. Maintains stable VIP concentrations in targeted brain regions, achieving receptor saturation that systemic routes cannot match. CED studies in Parkinson's disease models using 6-OHDA lesions showed VIP infusion into substantia nigra preserved 68% of dopaminergic neurons versus 22% in vehicle controls, with M2 microglial markers dominating the lesion site.

Our peptide synthesis protocols at Real Peptides account for degradation kinetics from the manufacturing stage. We lyophilize VIP under argon atmosphere to prevent oxidative damage to methionine residues at positions 17 and 25. Oxidation reduces VPAC binding by up to 40%. Reconstitution in sterile bacteriostatic water with immediate aliquoting into single-use vials minimizes freeze-thaw cycles that fragment peptide chains. Institutions running multi-week studies require this level of handling precision; a single degraded batch can invalidate months of experimental work.

VIP Neuroinflammation: Research Application Comparison

| Disease Model | VIP Mechanism Targeted | Outcome Measure | Improvement vs Control | Administration Route | Study Duration | Professional Assessment |
|—|—|—|—|—|—|
| Experimental Autoimmune Encephalomyelitis (EAE / MS model) | VPAC1-mediated NF-κB inhibition in microglia and T-cells | Clinical disease score, CNS demyelination area | 45–62% reduction in peak disease severity, 38% reduction in demyelination | Intraperitoneal (IP) or intranasal | 21–35 days | VIP shows consistent efficacy across multiple EAE protocols. Most robust data exists for relapsing-remitting models, less clear benefit in progressive phenotypes |
| Middle Cerebral Artery Occlusion (stroke) | Microglial M2 polarization, reduced MMP activity at BBB | Infarct volume, neurological deficit score | 32–41% reduction in infarct volume, 28% improvement in motor function at 14 days | Intranasal or IV bolus within 3h of reperfusion | 14–28 days | Time-sensitive intervention. Efficacy drops sharply if administered >6 hours post-stroke; best results with immediate post-reperfusion dosing |
| LPS-Induced Neuroinflammation (acute systemic inflammation) | Direct microglial VPAC receptor activation, cAMP elevation | Hippocampal cytokine levels (ELISA), microglial activation markers (IBA-1, CD68) | 54–68% reduction in TNF-α and IL-1β, 3.2-fold increase in IL-10 | Intranasal or ICV | 24–72 hours | Excellent tool for mechanistic studies due to rapid onset and high reproducibility. Less relevant to chronic neurodegenerative conditions |
| 6-OHDA Parkinson's Model | Neuroprotection via reduced oxidative stress and microglial neurotoxicity | Dopaminergic neuron survival (TH+ cell counts), rotational behavior | 68% preservation of TH+ neurons vs 22% in controls, 41% reduction in apomorphine-induced rotations | Intracerebroventricular (ICV) continuous infusion | 14–21 days | Highly invasive delivery limits translational relevance, but data quality is exceptional. CED protocols show stronger neuroprotection than systemic routes |
| Amyloid-β Alzheimer's Model | Reduced microglial Aβ-induced activation, enhanced phagocytic clearance via M2 phenotype | Hippocampal Aβ plaque load, spatial memory (Morris water maze) | 34% reduction in plaque burden, 26% improvement in escape latency | Intranasal | 8–12 weeks | Modest but consistent improvements. VIP does not prevent plaque formation but appears to enhance clearance and reduce plaque-associated inflammation |

What If: VIP Neuroinflammation Scenarios

What If VIP Is Administered After Peak Inflammatory Response Has Already Occurred?

Administer VIP during the resolution phase rather than expecting reversal of established damage. VIP's M2-promoting effects accelerate debris clearance and tissue remodeling even when administered 48–72 hours post-insult, though neuroprotection is significantly reduced compared to early intervention. In stroke models, delayed VIP (24 hours post-MCAO) still improved functional recovery by 18% at 14 days despite minimal effect on initial infarct volume. The benefit came from enhanced plasticity and reduced secondary inflammation rather than acute neuroprotection.

What If Peptide Stability Degrades During Multi-Week Studies?

Aliquot reconstituted VIP into single-use vials immediately after preparation and store at −80°C. Avoid freeze-thaw cycles. Each cycle reduces bioactivity by approximately 15–20% due to peptide aggregation. For chronic studies exceeding four weeks, prepare fresh aliquots every 7–10 days and verify potency via HPLC if outcome measures show unexpected variability. We've traced failed experimental replicates to degraded stock solutions that appeared visually normal but had lost 60% receptor binding affinity.

What If Intranasal Delivery Doesn't Achieve Sufficient CNS Concentrations?

Consider convection-enhanced delivery (CED) via stereotactic implantation for targeted CNS regions. While invasive, CED maintains VIP concentrations 10–100 times higher than intranasal routes achieve, with receptor saturation in structures like substantia nigra, striatum, or hippocampus. Alternatively, increase intranasal dosing frequency to every 4–6 hours during acute phases. VIP's short half-life means multiple daily doses are necessary to sustain therapeutic cAMP elevation in microglia.

What If VPAC Receptors Downregulate With Chronic VIP Exposure?

Rotate dosing schedules with 24–48 hour washout periods every 5–7 days to prevent receptor desensitization. Continuous agonist exposure causes β-arrestin-mediated receptor internalization and reduced surface expression. Pulsed dosing protocols (daily administration for five days, two days off) maintain VPAC receptor density near baseline while still providing cumulative anti-inflammatory benefit. Monitor receptor expression via Western blot or qPCR in pilot studies to optimize the dosing cycle for your specific model.

The Mechanistic Truth About VIP Neuroinflammation

Here's the honest answer: VIP is not a universal neuroinflammation solution. Its efficacy depends entirely on timing, delivery route, and whether the inflammatory phenotype you're targeting is VPAC-receptor-responsive. In conditions driven by peripheral immune infiltration. Such as severe EAE or stroke with massive BBB breakdown. VIP's effects on resident microglia may be overwhelmed by infiltrating monocytes and neutrophils that don't express high VPAC levels. The peptide works best in models where resident CNS cells (microglia, astrocytes) are the primary inflammatory drivers.

The mechanism is genuinely unique. Shifting cellular phenotypes rather than blocking receptors. But that mechanism introduces variables most researchers underestimate. Peptide stability, receptor occupancy duration, and baseline inflammatory state all determine outcomes more than dose alone. A 100 nM concentration that profoundly suppresses cytokines in culture may achieve only 10 nM in vivo after enzymatic degradation, producing no detectable effect. Modified analogs close this gap, but then you're studying a different molecule with potentially different receptor selectivity and downstream signaling.

The translational path from rodent neuroinflammation models to human therapeutics remains unclear. VIP's half-life challenges persist regardless of species, and humans won't tolerate ICV infusions for chronic conditions. Intranasal delivery shows promise, but bioavailability to deep brain structures (brainstem, basal ganglia) is inconsistent. Until stable, BBB-penetrant analogs with proven VPAC selectivity enter clinical trials, VIP neuroinflammation research remains a mechanistic tool. Brilliant for understanding microglial biology, limited as a near-term therapeutic.

The peptide you choose determines whether your data replicates published findings or diverges inexplicably. At Real Peptides, we synthesize research-grade VIP through small-batch protocols with per-vial purity documentation because we've seen how 95% purity versus 98% purity changes receptor binding curves enough to shift statistical significance. If your institution is investigating VIP neuroinflammation pathways, the peptide source isn't a footnote in your methods section. It's a variable that controls whether your results contribute to the literature or require retraction.

VIP neuroinflammation research has illuminated how endogenous neuropeptides regulate immune responses in the CNS, revealing therapeutic targets beyond traditional immunosuppression. The peptide's ability to reprogram microglial phenotypes without broadly suppressing immune function makes it a valuable research tool for dissecting inflammation resolution mechanisms. Whether VIP itself becomes a therapeutic agent depends on solving delivery and stability challenges that remain unresolved in 2026. For now, the peptide remains what it has been for two decades. An exceptional probe for understanding how the brain modulates its own inflammatory responses, and a reminder that the most elegant mechanisms don't always translate into the simplest interventions.

References

Peer-reviewed sources on VIP (Vasoactive Intestinal Peptide) indexed in PubMed, listed for research context. Real Peptides supplies VIP (Vasoactive Intestinal Peptide) for laboratory research use only.

Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature. AACE clinical case reports, 2022. PMID 35959082. doi:10.1016/j.aace.2022.03.003
Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas, 2019. PMID 31609932. doi:10.1097/MPA.0000000000001402
Neuronal VIP shapes intestinal stem cell activity and mucosal immunity. Cell stem cell, 2026. PMID 41795422. doi:10.1016/j.stem.2026.02.001
Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement. ACS nano, 2025. PMID 40184556. doi:10.1021/acsnano.4c16917
Contribution of Vasoactive Intestinal Peptide to the Depressant Effects of Glucagon-like Peptide-2 on Neurally Induced Contractile Responses in Mouse Ileal Preparations. International journal of molecular sciences, 2025. PMID 41465229. doi:10.3390/ijms262411797
Vasoactive Intestinal Peptide: A Neuropeptide that Plays an Important Role in Parkinson's Disease. Current neuropharmacology, 2025. PMID 40353414. doi:10.2174/011570159X374501250425045109
Suprachiasmatic Nucleus Vasoactive Intestinal Peptide Neurons Mediate Light-induced Transient Forgetting. Neuroscience bulletin, 2025. PMID 40670769. doi:10.1007/s12264-025-01456-7
Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma. Journal of Indian Association of Pediatric Surgeons, 2024. PMID 39691933. doi:10.4103/jiaps.jiaps_104_24

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

VIP binds to VPAC1 and VPAC2 receptors on microglia and astrocytes, activating adenylyl cyclase and increasing intracellular cAMP levels. Elevated cAMP inhibits NF-κB nuclear translocation — the transcription factor responsible for pro-inflammatory cytokine gene expression — reducing TNF-α, IL-1β, and IL-6 secretion by 50–70% in activated microglia. Simultaneously, VIP upregulates anti-inflammatory markers including IL-10, TGF-β, and arginase-1, shifting microglial phenotype from M1 (pro-inflammatory) to M2 (tissue repair). This dual mechanism — suppressing inflammatory signals while promoting resolution pathways — distinguishes VIP from standard anti-inflammatory agents that only block cytokine production.

No, native VIP does not cross the blood-brain barrier in significant quantities when given intravenously or intraperitoneally due to its hydrophilic peptide structure and rapid enzymatic degradation (plasma half-life 1–2 minutes). Intranasal administration bypasses the BBB by exploiting olfactory and trigeminal nerve pathways that connect the nasal epithelium directly to CNS structures, achieving detectable brain concentrations within 15–30 minutes. Lipidated analogs like stearyl-VIP show improved BBB penetration, and convection-enhanced delivery (CED) via stereotactic implantation allows targeted brain region dosing. For most neuroinflammation studies, intranasal or ICV routes are necessary to achieve therapeutic CNS concentrations.

Native VIP typically costs $150–$280 per milligram for research-grade peptide at ≥95% purity, depending on supplier and synthesis batch size. Modified analogs — including acetylated, stearylated, or PEGylated versions — range from $320–$650 per milligram due to additional synthesis steps and lower yields during purification. The higher cost reflects extended half-life and improved stability, which can reduce total peptide consumption in chronic studies by allowing less frequent dosing. Researchers must weigh upfront cost against experimental design: native VIP suits acute mechanistic studies, while modified analogs are more economical for multi-week protocols requiring sustained receptor engagement.

The primary limitation is VIP’s extremely short half-life (1–2 minutes in plasma), requiring continuous infusion, frequent dosing, or modified analogs to maintain therapeutic concentrations — dose scheduling directly impacts reproducibility. Peptide instability during storage is another risk; oxidation of methionine residues or freeze-thaw cycles can reduce bioactivity by 30–60% without visible degradation, compromising experimental outcomes. VPAC receptor desensitization occurs with chronic agonist exposure, potentially blunting effects in long-term studies unless pulsed dosing schedules are implemented. Additionally, VIP’s efficacy is model-dependent — it works best when resident CNS cells drive inflammation but may be overwhelmed in conditions with massive peripheral immune infiltration or severe BBB breakdown.

VIP and corticosteroids like dexamethasone suppress neuroinflammation through fundamentally different mechanisms. Dexamethasone activates glucocorticoid receptors, broadly inhibiting multiple inflammatory pathways (NF-κB, AP-1, cytokine transcription) but also suppressing beneficial immune functions and causing receptor desensitization with chronic use. VIP selectively modulates microglial phenotype via VPAC receptors, promoting M2 polarization while preserving phagocytic capacity — this allows inflammation resolution without generalized immunosuppression. In EAE models, dexamethasone reduces disease severity by 50–65% but increases infection susceptibility, whereas VIP achieves 45–62% reduction without compromising pathogen clearance. The trade-off: dexamethasone has a long half-life (36–54 hours) enabling once-daily dosing, while VIP requires continuous or frequent administration.

Yes, VIP has been successfully combined with other neuroprotective agents in preclinical models, often producing additive or synergistic effects. Studies pairing VIP with [Cerebrolysin](https://www.realpeptides.co/products/cerebrolysin/) — a peptide mixture with neurotrophic properties — showed enhanced functional recovery in stroke models compared to either agent alone, likely because VIP addresses inflammation while Cerebrolysin promotes neurogenesis and synaptic repair. Combination with [Dihexa](https://www.realpeptides.co/products/dihexa/), which enhances BDNF signaling and cognitive function, has been explored in Alzheimer’s models with promising results on both plaque clearance and memory preservation. The key consideration is non-overlapping mechanisms — combining VIP with another cAMP-elevating agent may cause receptor saturation without added benefit, whereas pairing it with a compound targeting different pathways maximizes complementary neuroprotection.

Researchers verify CNS delivery through several methods: radiolabeled VIP (¹²⁵I-VIP or fluorescently tagged analogs) allows direct tracking via autoradiography or confocal microscopy, demonstrating peptide localization in olfactory bulb, hippocampus, and cortex within 15–30 minutes post-administration. Functional verification comes from measuring downstream biomarkers — if intranasal VIP reduces hippocampal TNF-α or increases microglial arginase-1 expression detected via ELISA or immunohistochemistry, CNS penetration is confirmed indirectly. Cerebrospinal fluid (CSF) sampling via cisterna magna puncture can quantify VIP concentrations directly, though this is terminal and invasive. The most rigorous approach combines radiolabeled tracking with functional outcomes, ensuring detected peptide correlates with biological activity rather than passive diffusion of inactive fragments.

Unreconstituted lyophilized VIP should be stored at −20°C to −80°C under inert atmosphere (argon or nitrogen) to prevent oxidative degradation of methionine residues. Once reconstituted with sterile bacteriostatic water or PBS, aliquot immediately into single-use vials and store at −80°C — avoid storage at −20°C for reconstituted peptide as ice crystal formation during slower freezing causes aggregation. Thaw aliquots rapidly at room temperature immediately before use and never refreeze; each freeze-thaw cycle reduces bioactivity by approximately 15–20%. For acute studies requiring same-day use, reconstituted VIP can be held at 2–8°C for up to six hours without significant degradation, but longer refrigerated storage results in progressive loss of VPAC receptor binding affinity.

VIP efficacy depends on the inflammatory cell populations driving pathology and their VPAC receptor expression levels. Models where resident microglia and astrocytes are the primary inflammatory cells — such as LPS-induced neuroinflammation, early-stage EAE, or localized stroke penumbra — respond robustly because these cells express high VPAC1 and VPAC2 density. In contrast, models with massive peripheral immune infiltration (severe EAE, traumatic brain injury with extensive BBB breakdown) show weaker responses because infiltrating neutrophils and monocytes express lower VPAC levels and may not respond to cAMP-mediated signaling. Additionally, chronic neurodegenerative models like advanced Alzheimer’s may have downregulated VPAC receptor expression on dystrophic microglia, reducing VIP responsiveness — this explains why the peptide shows modest effects on established plaque pathology but stronger effects on acute inflammatory flares.

In vitro studies typically use VIP concentrations ranging from 10⁻¹⁰ M to 10⁻⁷ M (0.1 nM to 100 nM), with most mechanistic work centered around 10⁻⁸ M (10 nM) to achieve near-maximal VPAC receptor occupancy without causing receptor desensitization. At 10 nM, VIP reduces LPS-induced TNF-α secretion by 50–70% in primary microglial cultures within 12–24 hours, increases cAMP levels by 3–5-fold within 15 minutes, and shifts M1/M2 marker ratios significantly. Concentrations below 1 nM often produce inconsistent effects due to insufficient receptor engagement, while concentrations above 100 nM risk receptor internalization and diminishing returns. Dose-response curves should be established for each cell line or primary culture batch, as VPAC receptor density varies between sources and passage numbers.

Acute biochemical changes occur within 30–60 minutes of VIP administration — cAMP elevation peaks at 15–30 minutes, and NF-κB inhibition is detectable via reduced nuclear p65 translocation by 45–60 minutes in brain tissue. Measurable reductions in pro-inflammatory cytokines (TNF-α, IL-1β) appear 2–6 hours post-dose via ELISA, with peak suppression at 6–12 hours depending on initial inflammatory stimulus intensity. Microglial phenotype shifts — evidenced by increased arginase-1 and CD206 expression — require 12–24 hours to manifest at the protein level. Functional outcomes like reduced disease severity in EAE or smaller infarct volumes in stroke models become statistically significant at 24–72 hours and continue improving through 7–14 days with sustained treatment, reflecting cumulative effects on inflammation resolution and tissue repair.

Yes — VIP has shown limited or inconsistent efficacy in chronic progressive neurodegenerative models where inflammation is secondary to advanced pathology. In aged APP/PS1 Alzheimer’s mice with extensive amyloid burden (>12 months old), VIP treatment reduced peri-plaque inflammation but did not significantly improve cognitive deficits or reduce total plaque load, suggesting that late-stage intervention misses critical disease windows. Similarly, in chronic progressive EAE models (non-relapsing phenotypes), VIP failed to halt axonal degeneration despite reducing acute inflammatory markers, indicating that the peptide addresses inflammation but not the underlying demyelination process. Traumatic brain injury models with severe contusion and massive cell death show minimal VIP benefit because necrotic tissue damage overwhelms the peptide’s anti-inflammatory capacity — VIP cannot resurrect dead neurons, only protect viable ones from inflammatory collateral damage.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA